Limited US real-world evidence exists on the effect of substantial changes in weight on HbA1c among people with T2D. People with T2D were identified from 2010-2018 in the IQVIA Ambulatory EMR database. The date of the first observed weight value was defined as the index date and patients were required to have an additional weight value at 1 year (±90 days) post-index date. Patients were stratified by weight change between index and 1 year post-index date. HbA1c was evaluated at index, 6 months, and 1 year post-index date. Of the 1,061,354 patients evaluated, 20.2% gained weight, 53.9% had no weight change, and 10.6% lost 3-5%, 10.7% lost 5-10%, 2.8% lost 10-15%, and 1.7% lost ≥15% of their weight at the index date (i.e., index weight) at 1 year of follow-up. Of note, patients with the largest weight loss had the highest index weight (range: 203.7lb in patients with weight gain to 245.9lb in patients with ≥15% weight loss) . Mean index HbA1c was similar across subgroups as was the percent of patients with index HbA1c <7.0%. At both 6 months and 1 year post-index date, patients with ≥15% weight loss had the largest reduction in HbA1c and the highest percent of patients with HbA1c <7.0%.
In summary, HbA1c reduction was greater with increasing amount of weight lost during the one year of follow-up. Patients with weight loss ≥15% reduced HbA1c by an average of 1.2% of the index value at 1 year of follow-up.
S.Shinde: None. V.Thieu: None. A.Kwan: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. K.F.Houghton: None. D.Schapiro: Employee; Eli Lilly and Company. J.Meyers: Other Relationship; Eli Lilly and Company.
